Immunovant reports Q1 FY2026 net loss of $153.2M; cash $797.8M, pipeline on track

Immunovant, Inc.

Net loss of $153.2M ($0.75/share) vs $120.6M ($0.71/share) YoY; non-GAAP net loss $139.4M.
Cash and equivalents $797.8M as of June 30, 2026, providing runway to potential IMVT-1402 launch in Graves' disease.
R&D expenses $142.6M (GAAP) vs $101.2M YoY, driven by IMVT-1402 clinical trial costs.
Pipeline on track: topline data for D2T RA and CLE in H2 2026; GD and MG in 2027; CIDP and SjD in 2028.
G&A expenses decreased to $17.7M from $26.0M YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.